YONKERS, N.Y.--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) announced today that the Company has received approval from the United States Food and Drug Administration ( FDA ) for its Investigational New Drug (IND) application for the systemic use of AVR118 in patients with advanced malignancies. ADVR h
COLUMBUS, Ohio -- E Med Future, Inc. (OTCBB:EMDF) has received a five million dollar ($5,000,000) purchase order for NeedleZap(R), a device that disintegrates used injection needles, from the International Africa AIDS Foundation, said Dane Donohue, Executive Vice President. According to Donohue, Ray Bailey, Chairman of
MEDFORD, NY -- Chembio Diagnostics, Inc. (OTCBB:CEMI) today announced that it has completed clinical trials on two HIV rapid tests, HIV Stat Pak and Sure Check(TM) HIV, with results which meet current FDA expectations for specificity and sensitivity.. The completion of these clinical trials enables the company to submi
NEW YORK & FOSTER CITY, Calif. -- Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences , Inc. (Nasdaq:GILD) today announced details of a joint venture to develop and commercialize the fixed-dose combination of Bristol-Myers Squibb s Sustiva (R) (
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that its Hemopurifier(TM) treatment technology has demonstrated multi-pathogen clearance capabilities that could lead to a simultaneous treatment for persons infected with both HIV and the Hepatitis C virus (HCV). The Hemopurifier is a medical device that
-- CE Marking Clears Way for Commercialization of the System in European Union and Other Parts of the World EMERYVILLE, Calif. & SAN DIEGO -- Chiron Corporation (Nasdaq:CHIR) and Gen-Probe Incorporated (Nasdaq:GPRO) today announced that the PROCLEIX(R) ULTRIO(TM) Assay for use on the PROCLEIX(R) TIGRIS(R) System ha
WASHINGTON-- The United States House of Representatives Committee on Government Reform will conduct a hearing on Tuesday, December 14, 2004, 2:00 PM, Rayburn Building, Room 2154, regarding the Hepatitis C epidemic. Stalking a Furtive Killer: A Review of the Federal Government s Efforts to Combat Hepatitis C, and will
BOYNTON BEACH, Fla. -- Nutra Pharma Corp., (OTCBB:NPHC) a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis (MS) today announced that it has engaged Eno Research and Development, Inc. (ERDI) to validate the technology o
MINNEAPOLIS -- Chronimed Inc. (Nasdaq:CHMD) announced today that the Health Resources and Services Administration (HRSA) of the Federal Government awarded it a one year contract as exclusive distributor of HIV medications for approximately 1,700 clients on certain State AIDS Drug Assistance Program (ADAP) waiting lists
SPARKS, Nev. -- Bilingual Health Station Offers Los Angeles Residents Access to Vital Treatment and Prevention Information Computerized Screening, Inc. (CSI), today announced an agreement with the City of Long Beach Department of Health and Human Services (DHHS) to place a customized version of CSI s Health Station, an
SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that Chief Technical Officer Joan M. Robbins, Ph.D., will present on the Company s EradicAide(TM) HIV therapeutic vaccine program at 5:00pm on Thursday, December 2, at a vaccines conference organized by GTCbio. The conference, entitled Vaccines - A
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today opened The NASDAQ Stock Market in recognition of World AIDS Day, commemorated annually on December 1. OraSure President and CEO, Douglas A. Michels, presided over The NASDAQ Market Open ceremony this morning i
NEW YORK -- Members of the financial services industry and their guests met today to discuss HIV/AIDS and its effect on the global economy. United Nations Secretary-General Kofi Annan addressed a gathering of more than 300, including executives from Credit Suisse First Boston, Goldman Sachs, JPMorgan Chase, Lehman Brot
YONKERS, N.Y. -- ADVR will Report Results on its Phase I/II Clinical Trial of AVR118 in Patients with AIDS Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that James T. D Olimpio, M.D., has been invited to give an oral presentation at the 2005 Annual Assembly of the American Academy of Hospice
SAN DIEGO -- One of the most ambitious AIDS awareness campaigns ever undertaken in India kicks off on December 1, 2004, with the launch of a year-long, 6,000-kilometer AIDS Walk for Life that aims to educate millions about the nature of the disease and how they can stop the spread of AIDS. With financial support fr
SOUTH JORDAN, Utah -- ISIPS, the first international needlestick prevention group, announced that five recipients are being honored for reducing sharps injuries with a Sharps Injury Prevention Award with an additional two recipients receiving honorable mention awards. These awards are part of the International Sharps I
OCEANSIDE, Calif. -- SeraCare Life Sciences, Inc. (Nasdaq: SRLS), a provider of biological materials and services essential for research applications, the manufacture of diagnostic tests and the commercial production of therapeutic drugs, today announced FDA clearance for three new ACCURUN(R) quality controls, sold thr
LAS VEGAS-- Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- Animated Video Highlights Uniqueness of sPHirewall -- HIV Drugs Could Be First Oral Entry Inhibitors Samaritan Pharmaceuticals Inc., a developer of innovative drugs to target AIDS, Alzheimer s and cardiovascular disease, announced that today they will showcase t
SACRAMENTO, Calif. -- BloodSource has been selected to participate in a $2.4 million federal grant program to improve blood transfusion safety in African and Caribbean countries heavily affected by HIV/AIDS. As part of the federal Emergency Plan for AIDS Relief, BloodSource, along with Emory University, The American As
PHOENIX -- A Japanese herbal product, Sho-saiko-to (H09), is under a clinical phase II trial by Memorial Sloan-Kettering Cancer Center to determine its effect on hepatitis C patients. The preliminary results of the trial have been reported at the 1st Annual Society of Integrative Oncology Conference in New York on Nov.
LOS ANGELES -- The American International AIDS Foundation, publisher of AIDS.com, today announced the results of a year-long survey about AIDS and HIV, which asked about the opinions and certain behavior surrounding the disease. The survey was conducted through their website, www.AIDS.com, and they received an overwhel
LOS ANGELES -- Pastors from a state coalition formed to mentor African American churches in HIV/AIDS education efforts are disseminating HIV/AIDS Church Information Kits in concert with a massive push to get Black congregations tested for the disease. Within the past year, the Statewide HIV/AIDS Church Outreach Advisor
EMERSON, N.J.--Energex Systems, Inc. announced today that preliminary results of its Hepatitis C clinical trial have shown consistent and drastic reductions in viral load in trial participants treated with its Hemo-Modulator technology. The trial is being conducted under an Investigational Device Exemption (IDE) that w
FOSTER CITY, Calif.-- Gilead Sciences , Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast from the Punk, Ziegel & Company s Investor Symposium, New Agents to Treat HIV, in New York, NY. This webcast may be accessed via the company s corporate website at www.gilead.com. John F. M
WILMINGTON, Del.--Incyte Corporation (Nasdaq:INCY) announced today that Richard Levy, M.D., senior vice president, drug development of Incyte will present at the Punk, Ziegel & Company s Investor Symposium, New Agents to Treat HIV, on Monday, November 22, 2004 at 10:50 a.m. (ET). The presentation will be webcast li
FOSTER CITY, Calif.-- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has recommended granting a Marketing Authorisation for Truvada(TM) (emtricitabine and
COLUMBUS, Ohio -- E Med Future, Inc. (OTCBB:EMDF) is hosting a luncheon for dignitaries and Ambassadors from more than 20 African nations for a formal introduction of NeedleZap(R), a device that disintegrates used injection needles at their point of use. The event will take place at the University Club of Washington th
MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) announced today the publication of a research study expanding upon the use of telomerase activation to increase the lifespan and augment the antiviral activities of HIV-1 specific immune cells. The data support the development of Geron s small molecule telomerase ac
BOYNTON BEACH, Fla.-- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced the appointment of Stewart Lonky, MD, FACP, MBA to its Board of Directors. Dr. Stewart Lonky attended St. Law
CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today that Dr. John Bonfiglio, President and Chief Executive Officer, was interviewed by Aware Talk Radio, a national syndi
CARLSBAD, Calif.--The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today that the Canadian HIV Trials Network (CTN) has approved the Company s IR103-111 study for support. The CTN Steering Com
BOYNTON BEACH, Fla. -- Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has signed an Agreement to acquire 100% of Portage BioMed, LLC. The acquisition will be made through a restricted stock tr
DENVER -- The Legal Center for People with Disabilities has filed a charge of disability discrimination against Dr. Paul Cutarelli and Lasik Vision Institute. In its complaint to the Colorado Civil Rights Division, The Legal Center alleges that Lasik Vision Institute and Dr. Cutarelli refused service to an HIV-positive
YONKERS, N.Y.--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) announced today that it received the fourth installment of $3 million from James Dicke II and his son, James Dicke III. As announced, on February 3, 2004, ADVR entered into an agreement with the Dickes whereby ADVR agreed to sell an aggregate of 12
BOYNTON BEACH, Fla. -- Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that its holding, Infectech, Inc. (Pink Sheets: IFEC) has received further verification of its technology by
Interscience Conference on Antimicrobial Agents and Chemotherapy WASHINGTON -- Gilead Sciences (Nasdaq:GILD) today announced the presentation of 24-week data from an ongoing clinical trial (Study 934) that suggest treatment-naive patients with HIV who received a once-a-day regimen of
WASHINGTON -- Incyte Corporation(NASDAQ:INCY): -- Additional analysis of results of a 10 patient 10-day phase IIa study presented at ICAAC also suggest Reverset is effective for patients with viral mutations often seen in treatment with currently available nucleoside-analogue reverse transcriptase inhibitors Incyte Cor
SINGAPORE & NEW YORK -- The Novartis Institute for Tropical Diseases (NITD) and the Global Alliance for TB Drug Development (TB Alliance), a public-private partnership developing affordable new TB drugs, today announced plans to pursue a joint research program into novel, promising anti- tuberculosis agents.
EMERYVILLE, Calif. -- Chiron Corporation (Nasdaq:CHIR) today announced that it has granted to F. Hoffmann-La Roche (Roche) a nonexclusive license for the research, development and commercialization of small molecule therapeutics against hepatitis C virus (HCV) drug targets.
-- Once Daily Application May Improve Patient Compliance and Avoid Drug Interactions and Adverse Effects in Treatment of Oropharyngeal Candidiasis PARIS -- BioAlliance Pharma, a biopharmaceutical company focused on the field of drug resistance, today announced that a research team, including the company, reported resul
DURHAM, N.C.--Trimeris, Inc. (NASDAQ: TRMS) today announced financial results for the third quarter ended September 30, 2004. For the third quarter of 2004, the Company reported a net loss of $8.3 million, or ($0.38) per share, compared with a net loss of $16.6 million ($0.77) per share in the third quarter of 2003 and
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that the company is discontinuing its development programs for GS 9005 and GS 7340, two investigational products for the treatment of HIV. The company will continue to focus its research efforts on multiple targets for HIV, including
BETHLEHEM, Pa. - OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, announced today that it is launching its OraQuick(R) ADVANCE Rapid HIV-1/2 Antibody Test, the first and only U.S. Food and Drug Administration ( FDA ) approved and CLIA (Clinical Laboratory Improvements Amendments Ac
DURHAM, N.C. -- Trimeris, Inc. (Nasdaq: TRMS) today announced that net sales in the U.S. and Canada of Fuzeon for the third quarter were $21.1 million compared to net sales of $24.4 million in the second quarter. During the second quarter distribution was expanded beyond a single distributor, Chronimed, Inc., to multip
CLEVELAND -- Demand for vaccines in the US will advance 8.6 percent annually to $7.4 billion in 2008. Afterwards, new products for complex human diseases will lead to rapid acceleration in growth. Within the next few years, advances in biotechnology and related life sciences are expected to bring the first vaccines for
DURHAM, N.C. -- Merix Bioscience today announced the change of its name to Argos Therapeutics, Inc. Additionally, the company stated that it is preparing for an HIV clinical trial with Argos proprietary RNA-loaded dendritic cell vaccine. This change in name reflects the evolution and success of our technology platform,
LAS VEGAS & DUBLIN, Ireland -- Samaritan Pharmaceuticals Inc. -- Signs master collaboration agreement to produce clinical trial drug and full-scale manufacturing of pipeline drugs -- Creates a virtual in-house facility; eliminating the hiring of contract manufacturers, savings could amount to as much as $500,000 pe
AUSTIN, Texas -- LabNow, Inc., developer of a Point-of-Care diagnostic system, announced that it has raised $14 million in equity financing from a syndicate of private and venture investors led by George Soros, with the participation of Austin Ventures. Funds will be used to develop the company s technology and to laun
SAN DIEGO & EMERYVILLE, Calif. -- Gen-Probe Incorporated and Chiron Corporation announced today that a Biologics License Application (BLA) for the Procleix(R) Ultrio(TM) blood screening assay has been submitted to the U.S. Food and Drug Administration. The Procleix Ultrio Assay was developed to simultaneously detec
FOSTER CITY, Calif. -- Twenty-four Week Data Evaluating Viread (R) and Emtriva(R) Versus Combivir (R) in Combination with Efavirenz in Treatment-naive Patients with HIV to be Presented
PARIS -- BioAlliance Pharma: Study Points to Integrase as Possible Target for Novel Drugs BioAlliance Pharma, a biopharmaceutical company focused on the field of drug resistance, today announced that a research team, including the company, reported preclinical data demonstrating that styrylquinolines (SQs), a new famil
LARCHMONT, N.Y. -- Medication Adherence in HIV/AIDS is an invaluable resource for healthcare professionals faced with the daunting challenge of achieving new optimal treatment outcomes in patients with HIV/AIDS. Published by Mary Ann Liebert, Inc. (www.liebertpub.com), this compilation of cutting-edge reports captures
LEXINGTON, Mass. -- Indevus Pharmaceuticals, Inc. today announced that the Microbicide Development Programme (MDP) has selected PRO 2000, the Company s microbicide under development to prevent sexual infection by HIV, as the sole agent to be tested in full-scale clinical trials due to start next year in a number of Afr
SPARKS, Nev. -- HIV/AIDS Outreach Programs Can Use Health Stations to Deliver Critical Treatment Information to the Nearly 900,000 Infected Patients in the United States Computerized Screening, Inc. (CSI), today announced it has developed a customized version of its Health Station, an integrated health screening device
SAN DIEGO -- Aethlon Medical, Inc. announced that its Chief Scientific Officer, Dr. Richard Tullis will present today at the Global BioPharma Conference 2004, being held in Mumbai, India . The conference, which is a cooperative venture of The State University of New York (SUNY) and the Global BioPharma Conference Group
EMERYVILLE, Calif. -- Chiron Corporation today announced that Chiron had granted a nonexclusive license to InterMune, Inc. for the research, development and commercialization of therapeutics against hepatitis C virus (HCV) drug targets. Financial terms of the agreement were not disclosed. We are pleased to have wo
YONKERS, NY-- Advanced Viral Research Corp. announced today that the Company had a successful pre-IND (Investigational New Drug) meeting with the FDA at the end of August. Based on the results of the meeting, Advanced Viral Research Corp. believes it is well positioned to submit an IND application for the injectable us
LA JOLLA, Calif.-- The U.S. Food and Drug Administration ( FDA ) has granted Instead, Inc. clearance to market its personal lubricant product, Amphora(TM). In addition to its lubricating properties, Amphora has been shown, in early clinical and pre-clinical tests, to immobilize sperm for up to eight hours when applied
BOYNTON BEACH, Fla. -- Nutra Pharma Corp., a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced today that its majority owned subsidiary, Infectech, Inc. has received third party verification of its techno
BOYNTON BEACH, Fla. -- Nutra Pharma Corp., a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced today that its minority-owned holding, ReceptoPharm, Inc., has discovered the potential for widely available
PARIS -- BioAlliance Pharma SA, a privately held biopharmaceutical company focused on the field of drug resistance, today announced that it has raised an additional 2.0 million euros (2.4 million dollars) to top off its third round of financing at 12 million euros (14.7 million dollars). In a round led by Auriga Partne
FOSTER CITY, Calif.-- Gilead Sciences today announced preliminary data from a planned interim 24-week analysis of the company s ongoing Study 934. This study, a 48-week clinical trial, was designed to compare a regimen of Viread (R) (
HOUSTON -- American College of Acupuncture & Oriental Medicine (ACAOM) has partnered with Montrose Clinic to offer acupuncture to their patients. With the new agreement, ACAOM will fulfill one of its missions to provide service to the community by providing acupuncture treatments to HIV and AIDS patients. A United
BASKING RIDGE, N.J.-- Millennium Biotechnologies Pioneers Use of Defenzyme in Medical Nutrition for Immuno-Compromised Patients Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. is pleased to announce yet another major study validating the crucial benefits of SOD/Gliad
LITTLE ELM, Texas -- Retractable Technologies, Inc. announced today that it has been awarded a U.S. government contract to supply VanishPoint(R) safety syringes to five African countries under the Bush Administration s Global HIV/AIDS initiative (President s Emergency Plan). Under the contract, which is the first award
FOSTER CITY, Calif. - Provides Truvada to 68 Developing Countries at No-Profit Pricing Truvada Added to Patient Assistance Program in United States Gilead Sciences , Inc. has announced that it will provide access to Truvada(TM) (emtricitabine and
BASKING RIDGE, N.J. -- In a six-month study conducted at the Center for Family Health of St. Mary s Hospital, Hoboken, NJ, Resurgex, a patented multi-action, multi-component nutritional formula designed by Millennium Biotechnologies to address the comprehensive needs of individuals struggling with immuno-compromised co
CHICAGO -- The Pharmaceutical Press, the publications division of the Royal Pharmaceutical Society of Great Britain, with offices in London and Chicago, has published the first edition of The Medicinal Uses of Cannabis and Cannabinoids. The publication is an authoritative review of the development of cannabis-based med
YONKERS, N.Y.-- Advanced Viral Research Corp. announced today that all 30 patients have been enrolled in its Phase I/II clinical trial of AVR118 in patients with AIDS, thereby completing patient enrollment in this trial. This Phase I/II trial is being conducted at the Kaplan Medical Center in Israel in cache
YONKERS, N.Y. -- Advanced Viral Research Corp. announced today that it received the third of four $3 million payments from James Dicke II and his son James Dicke III. As announced, on February 3, 2004, ADVR entered into an agreement with the Dickes whereby ADVR agreed to sell an aggregate of 120,000,000 shares of ADVR
VANCOUVER, British Columbia -- Enterprise Technologies, Inc., is pleased to announce that its wholly owned subsidiary, Phytomedical Technologies Corporation (Phytomedical), has entered into an exclusive worldwide licensing agreement with New York University (NYU) for certain patented inventions ( NYU Patents ) related
EPZICOM(TM), a new product combining two HIV medicines into one tablet dosed once a day (QD) with no food or fluid requirements, has been cleared for prescription use by the U.S. Food and Drug Administration ( FDA ). EPZICOM combines two widely-used nucleoside reverse transcriptase inhibitors (NRTIs), EPIVIR(R) (lamivu
SAN DIEGO -- Cell Bio-Systems Inc., a biotechnology company positioned to manufacture and distribute patented, disposable technologies for stem cell research, cosmetic surgery and other living tissue procedures, announced today that it will be modifying its Super Luer Syringe Adapter to meet the need for disposable med
HOUSTON -- CytoGenix, Inc. announced the successful completion of pre-clinical animal safety studies. These standard studies show that the company s lead DNA anti-herpes topical compound is safe in three species of animals. A third party laboratory conducted the tests operating under FDA Good Laboratory Practices (G
NEW YORK -- Organetix Inc. announced today that it has received the results of its study to determine the effectiveness of its A4+L Liver Product on the quality of life of Hepatitis C patients. The study was designed by independent doctors in the USA and Peru and was conducted in Peru. Based on the results repor
FOSTER CITY, Calif. -- Gilead s Third HIV Therapeutic and Fourth Antiviral Approved in Three Years; Truvada Also Available Through Gilead Access Program for Developing World Gilead Sciences today announced that the U.S. Food and Drug Administration ( FDA ) has granted accelerated approval of Truvada(TM) (emtricitabi
PHILADELPHIA -- Hemispherx Biopharma, Inc. announced today that an abstract entitled Chronic Fatigue Syndrome (CFS): Phase III, Randomized, Double-Blinded Clinical Trial Shows Significant Improvement in the Primary Endpoint, Exercise Treadmill Duration, with Ampligen has been accepted by the 44th Interscience Conferenc
DEERFIELD, Ill. & CONCORD, Calif.-- Subsidiaries of Baxter International Inc. (NYSE:BAX) and Cerus Corporation today announced that they have entered into a definitive agreement with BioOne Corporation for commercialization of the INTERCEPT Blood System for platelets in parts of Asia. The INTERCEPT Blood System for
NEWPORT BEACH, Calif. -- Acacia Research Corporation announced today that its CombiMatrix group and collaborator irsiCaixa have entered into a three year research, development, and licensing agreement and have chosen two siRNA candidates for downstream pre-clinical development against HIV. These two compounds target tw
PITTSBURGH -- Alcoa Foundation today announced it has invested $200,000 in a two-year program implemented by Population Services International (PSI) to fight malaria in Boke prefecture in Guinea . The Alcoa Foundation grant will be used to launch a campaign to train healthcare workers in malaria prevention and to distr
BANGKOK, Thailand -- Progenics Pharmaceuticals, Inc. today announced that its human immunodeficiency virus (HIV) vaccine candidate stimulated the production of specific anti-HIV antibodies in animals. When tested in the laboratory, these antibodies inactivated certain strains of HIV isolated from infected patients. The
BEVERLY HILLS, Calif. -- Vencor International, Inc., a global manufacturer and distributor of healthcare products and services, announced the launch of its new E-commerce Business to Consumer healthcare products and services division, AtHomeDiagnostics.com (www.athomediagnostics.com). Vencor s AtHomeDiagnostics.com off
WHITEHOUSE STATION, N.J. -- Merck & Co. , Inc., (the parent company of MSD (Pty) Ltd. South Africa ) announced today that it has signed an agreement to grant a non-exclusive patent license for the manufacture and sale of a generic version of efavirenz to Thembalami Pharmaceuticals (Pty) Ltd., a local South African
STANFORD, Calif.-- Researchers from the Stanford University School of Medicine will discuss their most recent findings during the 15th International AIDS Conference in Bangkok beginning July 11. The topics they will discuss include testing the breast milk of infected mothers for the virus that causes AIDS, evaluating t
BANGKOK, Thailand-- Chembio Diagnostics, Inc., a leading point-of-care diagnostic company, today announced at the Fifteenth World Aids Conference that it has commenced clinical trials of the Sure Check(TM) HIV and HIV Stat-Pak - the company s proprietary lateral flow rapid tests for the detection of antibodies to HIV i
HAYWARD, Calif.-- Guava Assays Offer the Potential to Greatly Increase Global Access to Affordable, Accurate, and Easy-to-Perform HIV/AIDS Patient Monitoring Results from a multi-site study evaluating two new assays from Guava Technologies, Inc. that dramatically lower the cost and difficulty of AIDS diagnosis and trea
BANGKOK, Thailand-- Incyte Corporation. Patients with human immunodeficiency virus (HIV) who were treated for 10 days with Reverset(TM), a nucleoside-analogue reverse transcriptase inhibitor (NRTI) that is being developed as a once-a-day oral therapy for use in combination with other antiretroviral drugs, showed a redu
FOSTER CITY, Calif. -- Gilead Sciences today announced a significant price reduction for Viread (R) ( tenofovir disoproxil fumarate) in the developing world. Gilead provides Viread, a once-a-day antiretroviral medication f
LARCHMONT, N.Y. -- HIV-infected individuals who received five weeks of acupuncture treatment in a group setting reported decreased pain and reduced symptoms of peripheral neuropathy , according to a study published in the June 2004 issue (Volume 10, Number 3) of The Journal of Alternative and Complementary Medicine, a
LITTLE ELM, Texas-- Retractable Technologies, Inc., a leading maker of safety needle devices, today announced that it has settled its longstanding federal antitrust suit against Becton Dickinson (BD) for $100 million in cash. After legal fees and other expenses the company will receive the majority of these proceeds. T
PARIS -- BioAlliance Pharma, a biopharmaceutical company focused on the field of drug resistance, today announced that a research team from l Ecole Normale Superieure de Cachan, le Centre National de la Recherche Scientifique (CNRS), L Institut National de la Sante et de la Recherche Medicale (INSERM), and the Company
FALLS CHURCH, Va.-- Dr. Kenneth D. Kaunda, founding President of Zambia and founder of the Kaunda Foundation for the Relief of AIDS in Africa, today thanked Life Energy & Technology Holdings Inc. (OTCBB:LETH)(FWB:LFT) and Diamond Ridge Advisors for their help in the fight against AIDS in Africa. Dr. Kaunda cong
HOLLYWOOD, Fla.-- Phoenix Biosciences, Inc. (PBS), focused on developing affordable, non-toxic treatments for HIV/AIDS, announced today that the U.S. Patent and trademark office has granted PBS Patent Number 6,734,192. This patent was provided to Phoenix Biosciences, Inc., for their novel immunological method, which cl
BETHLEHEM, Pa.-- OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that the U.S. Food and Drug Administration ( FDA ), through its Center for Devices and Radiological Health, has approved a waiver under the Clinical Laboratory Improvements Amendments of 1988 ( CLIA ) for the Compa
BETHLEHEM, Pa. -- OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that it has received U.S. Food and Drug Administration ( FDA ) approval of its OraQuick(R) Rapid HIV-1/2 Antibody Test for use in detecting antibodies to the Human Immunodeficiency Virus Type 2, or HIV-2, in oral
BETHLEHEM, Pa. -- OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test will be donated to numerous locations across the United States to conduct free HIV testing in observance of National HIV Testing Day on June 27, 2004. Additionally, i
DURHAM, NC & TOKYO -- Merix Bioscience, a company pioneering therapeutic immunotherapy vaccines, and Kirin Brewery s Pharmaceutical Division, which is developing therapeutic products for renal disease, cancer and immunological disorders, today announced the signing of a collaboration agreement for developing therap
KINGSTON, Ontario, & MONTREAL -- Biosystemix joins S2K as partner to develop data-driven computational models that predict disease susceptibility and progression, and therapeutic response. Funded by Genome Canada and Genome Quebec, S2K s program, Functional Genomics, Pharmacogenomics and Proteomics of the Immune Re
BETHLEHEM, Pa. -- OraSure Technologies, Inc. announced today that it has received a worldwide, non-exclusive sublicense from Bio-Rad Laboratories under patents relating to the Human Immunodeficiency Virus, Type 2, or HIV-2. Bio-Rad is the exclusive licensee of Institut Pasteur of Paris, France , under the HIV-2 pat
SAN DIEGO -- Hollis-Eden Pharmaceuticals, Inc. today announced that it has named Jessie Groothuis, M.D., to the newly created position of Vice President, Clinical Affairs. In this position, Dr. Groothuis will be responsible for the operations aspects of the Company s clinical trial programs and will work closely with D
FARMINGDALE, N.Y.-- Enzo Biochem, Inc., announced today that the European Patent Office has granted it a patent that describes, in part, a method of performing targeted delivery and incorporation of genetic material into chromosomal DNA without using a viral vector, thus making possible the editing and correcting of ce
WILMINGTON, Del.-- Incyte Corporation announced today it will present at the Third Annual Needham Biotechnology Conference on Wednesday, June 16, 2004 at 9:30 a.m. (ET). Paul Friedman, MD., president and chief executive officer of Incyte, will provide an overview of the company and discuss its most advanced drug discov
SAN DIEGO -- Aethlon Medical Inc. announced today that it has completed a $673,000 private placement of common stock with accredited investors, including Fusion Capital Fund II LLC, a Chicago based institutional investor. Aethlon also announced that it has entered into a common stock purchase agreement with Fusion Cap
FARMINGDALE, N.Y.-- Enzo Biochem, Inc. announced today that the United States Patent and Trademark Office has issued to its subsidiary, Enzo Life Sciences, Inc., U.S. Patent No. 6,743,605 titled Linear Amplification of Specific Nucleic Acid Sequences surrounding methods of nucleic acid amplification. The newly patented
FARMINGDALE, N.Y.-- Enzo Biochem, Inc. announced today that the United States Patent and Trademark Office has issued to its subsidiary, Enzo Life Sciences, Inc., U.S. Patent No. 6,743,605 titled Linear Amplification of Specific Nucleic Acid Sequences surrounding methods of nucleic acid amplification. The newly patented
CAMBRIDGE, Mass.-- Phylonix today announced that it had recently received a Phase II Small Business Innovation Grant (SBIR) from the National Cancer Institute to develop zebrafish apoptosis assays for drug screening. The amount of the award is $993,463. Apoptosis is the genetically programmed process of precise, predic
LONDON -- FIT Biotech Oyj Plc is the recipient of Frost & Sullivan s 2004 European Excellence in Technology Award in the field of gene therapy and DNA delivery. The award recognizes the Finland-based company s efforts to develop innovative vaccines and gene therapies based on its proprietary gene delivery technolog
LONDON-- FIT Biotech Oyj Plc is the recipient of Frost & Sullivan s 2004 European Excellence in Technology Award in the field of gene therapy and DNA delivery. The award recognizes the Finland-based company s efforts to develop innovative vaccines and gene therapies based on its proprietary gene delivery technology
NEW YORK -- Organetix Inc. has commenced a new patient study to ascertain the effectiveness of its A4+L Liver Product relating to the quality of life of Hepatitis C patients. Specific criteria has been established by the medical team to scientifically measure the quality of life results of our product on ten new Hepati
STANFORD, Calif.-- Doctors may someday have a new way to combat AIDS by going straight to the source: destroying the virus before it has a chance to wreak havoc on a patient s immune system. Thomas Merigan, MD, the George and Lucy Becker Professor of Medicine in infectious diseases at Stanford University School of Medi
WHAT: Representatives from a newly formed coalition CURES - Californians United for Research, Economic Development and Saving Lives - will come together for a media roundtable discussion on Tuesday, May 25 to oppose legislation related to the development, procurement and regulation of Canadian prescription drugs. CURES
SANTA FE, N.M.-- Peggy C. Pence, PhD, has joined the Board of Directors of CytoDyn, Inc., a development stage biotechnology company that specializes in therapies for immunologically mediated diseases. Dr. Pence, a graduate of Louisiana Tech and Indiana University, has 30 years of experience in pharmaceutical research a
RANDLEMAN, N.C.-- Van loads of bandages, peroxide, aspirin, crutches and other items were delivered to Victory Junction Gang Camp today by volunteers from GlaxoSmithKline (GSK). Employees from the company s Parsippany, Philadelphia-area, Pittsburgh and Research Triangle Park offices contributed supplies for the Goody
FARMINGDALE, N.Y.-- Enzo Biochem, Inc., a leading biotechnology company, announced today that the Company has received approval in Israel to begin a Phase I clinical trial to study safety of its new immunomodulatory agent, EGS21, a beta-D-glucosylceramide compound (GC), in human subjects. The study, to be conducted at
Hepatitis C Trials; Earns $1,000,000 Milestone Payment SAN MATEO, Calif.-- SciClone Pharmaceuticals, Inc. today announced that a total of 1,000 patients have been enrolled in its two U.S. phase 3 hepatitis C (HCV) clinical trials evaluating its lead product ZADAXIN(R). SciClone has earned a $1,000,000 milestone payment
SAN DIEGO-- Hollis-Eden Pharmaceuticals, Inc. today announced that it will present at the UBS 2004 Global Specialty Pharmaceuticals Conference in New York City, at 9:00 a.m. Eastern (6:00 a.m. Pacific) on Tuesday, May 25, 2004. Presenting on behalf of the Company will be Daniel D. Burgess, CFO and COO. A live webcast o
MOUNTAIN VIEW, Calif.-- Pathways has many human interest stories to be told. In addition, as the Bay Area s leading provider of in-home care and hospice services, the following members of the Pathways executive team are available for interviews and background comments about industry trends; issues and topics concerning
LINCOLNSHIRE, Ill.-- Our nations 1st line of defense in the war on Sexually Transmitted Diseases (STDs) has been condoms. Recent headlines indicate they are not getting the job done. Syphilis falls here as US rates rise (Chicago Tribune 3/9/04). Survey: Adults still skip condom use (CNN 4/06/04). Why then do sexually a
BLUE BELL, Pa.-- Patent Covers Major Advance in Novel Drug Design Methods Locus Pharmaceuticals today announced that the US Patent and Trademark Office issued U.S. Patent No. 6,735,530 B1, entitled Computational Protein Probing to Identify Binding Sites , on May 11, 2004. The patent protects an innovative computational
BOYNTON BEACH, Fla.-- Nutra Pharma Corp., a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis, today announced that its subsidiary, ReceptoPharm Inc., has successfully cloned the gene required for the recombinant produc
FOSTER CITY, Calif.-- Gilead Sciences today announced that the U.S. Food and Drug Administration ( FDA ) has granted priority review status to the New Drug Application (NDA) for the fixed dose co-formulation of the company s anti-HIV medications Vir
PHILADELPHIA-- Glen Hurricane Schwartz Will Be Master of Ceremonies as Calcutta House Dedicates Its Newest Facility, Serenity Court Calcutta House, a non-profit, premier provider of supportive housing and services for individuals living with AIDS in Philadelphia, continues its mission and expansion with the dedication
NEW YORK & FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J.-- Companies Support U.S. Department of Health and Human Services Call to Increase Treatment Options for HIV in Developing World Bristol-Myers Squibb Company , Gilead Sciences , Inc. and Merck & Co. , Inc. announced tod
LAS VEGAS -- Samaritan Pharmaceuticals Inc.: -- Broadens and Diversifies Samaritan s HIV Pipeline -- Licensed Innovations Have Potential to Address Serious and Growing Concerns -- As With Samaritan s Lead HIV Drug SP-01A, Initial Preclinicals Suggest Additional Drugs Prevent HIV Viral Replication Samaritan Pharmaceutic
-- Key Collaboration with the World Foundation Aids Research and Prevention PHILADELPHIA-- Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that it entered into an agreement with the World Foundation Aids Research and Prevention to launch a clinical trial in HIV with its experimental product Alferon LDO(R), a low
DUBLIN, Ireland-- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Pipeline Insight: HIV - Enter the New Generation Inhibitors to their offering. Currently there is a range of marketed antiretrovirals for the treatment of HIV, the majority of which were launched between the years 1
LAS VEGAS--Samaritan Pharmaceuticals Inc. : -- FDA Transfers IND Application to Antiviral Division -- Encouraging Antiviral Data Suggests Lead and Second Generation HIV Drugs, Effective for HIV Drug Resistance as Entry Inhibitor Drug -- New HIV Patent Applications Filed For Drug Resistance Samaritan Pharmaceuticals
AMSTERDAM, The Netherlands-- Leaders in Air Express Delivery and Pharmaceutical Innovation Collaborate to Expand Access to HIV Care and Treatment DHL and Merck Sharp & Dohme (MSD)(1) today announced that they have signed an agreement that commits them to work together to expand access to critically-needed HIV medic
HAYWARD, Calif.-- -- Results Comparable to Standard CD4 Testing Methods with Dramatically Lower Price, Greater Ease of Use Medical laboratories in resource poor countries can now monitor direct, absolute CD4 (and CD8) T cell counts in HIV-infected patients faster, more easily and up to 20 times more affordably than eve
LONDON -- Progenics Pharmaceuticals, Inc. today announced that it has begun phase 1 clinical trials of a new HIV therapy - a humanized monoclonal antibody that blocks infection by inhibiting the ability of the virus to enter healthy cells. PRO 140 belongs to a new class of drugs, viral-entry inhibitors, which are desig
LOS ANGELES -- SRD Pharmaceuticals, Inc. today announced it has acquired 4 U.S. patents, 16 corresponding foreign patents and 4 additional patents pending from Nissin Foods, Ltd. of Japan . The acquisition includes the associated technologies and FDA filings related to an AIDS drug developed by Nissin s Molecular Biolo
BLUE BELL, Pa.-- Locus Pharmaceuticals today announced that is was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health for The Design and Development of Potent gp41 Inhibitors. This fully funded award of $180,000 will be used to support the development of novel, drug
FOSTER CITY, Calif. -- Gilead Sciences , Inc. today announced that it is expanding and simplifying its U.S. patient assistance program, Commitment to Access, which provides patients who have limited payment options access to Gilead medications free of charge. The redesigned program now enables people living with HIV wh
WOODLAND HILLS, Calif. -- Advanced Biotherapy, Inc. today announced the launch of a Phase I FDA-approved clinical trial to initially treat antiretroviral drug-resistant AIDS patients with an inhibitor to Tumor Necrosis Factor-alpha (TNF-alpha). The trial is being conducted by researchers at Georgetown University. The s
SAN DIEGO -- The State Department of Health Services, Office of AIDS, will contract with the Palliative Care Services of San Diego Hospice & Palliative Care Corp. (SDHPC) to begin offering the AIDS Medi-Cal Waiver Care Management Program. The AIDS Medi-Cal Waiver Program is a combination of care management and purc
BEVERLY HILLS, Calif. -- Vencor International, Inc. announced that it is expanding its newly developed relationship with Home Access Health Corporation, Hoffman Estates, Ill., by entering into a Memorandum of Understanding to develop international channels of distribution for HOME ACCESS(R) FDA approved at-home t
BERLIN -- Results of Largest Controlled Clinical Trial in Hepatitis B e Antigen-negative Patients; Resistance Analysis and Post-seroconversion Data Presented Gilead Sciences today announced 144-week data from a clinical trial (Study 438) of its oral antiviral drug Hepsera(R) (adefovir dipivoxil 10 mg) in patients with
BLUE BELL, Pa. -- Novel Anti-Inflammatory, Cancer and HIV/AIDS Drugs Identified and Advancing Toward IND Studies Locus Pharmaceuticals today announced the presentation of data during the Annual Keystone Structural Genomics meeting that demonstrates compelling crystallography-based confirmation of Locus computationally
SAN DIEGO -- Aethlon Medical, Inc. announced today that its Chairman and CEO, Mr. James A. Joyce will be a guest speaker at TechMed 2004, which is billed as Canada s largest Medical Device Partnering Symposium. The event will be held on April 26-28th at the Vancouver Pinnacle Marriott in Vancouver, BC. Mr. Joyce will d
LAS VEGAS -- Samaritan Pharmaceuticals Inc., a developer of innovative drugs to target AIDS, Alzheimer s and Cardiovascular disease, announces that since the beginning of the year, the Company has raised over $4.3 million in gross proceeds from institutional and accredited individual investors. The Company further anno
SAN MATEO, Calif.--(BUSINESS WIRE)--April 14, 2004--SciClone Pharmaceuticals today announced an ongoing randomized placebo-controlled clinical trial in Taiwan using a high dose of ZADAXIN(R) in combination with lamivudine, the most widely used treatment for chronic
AMHERST, N.H. -- With a total world market exceeding twelve billion units annually, syringe-based injection devices remain second only to oral drugs for the delivery of pharmaceuticals. New drug formulations, particularly large molecule biologicals that cannot tolerate the digestive tract, will keep syringes growing fo
GAITHERSBURG, Md. -- Gene Logic Inc. announced today that it has entered into a multi-year agreement with the National Cancer Institute, Division of Cancer Treatment and Diagnosis, to provide preclinical safety and pharmacology studies focused on NCI s core research areas of interest--cancer, AIDS and AIDS-related illn
PHOENIX -- Immune support, one of the fastest growing areas for dietary supplements in the United States and abroad, continues to intrigue consumers interested in protecting themselves against cellular damage and supporting their body s natural immunity. Now a new awareness campaign featuring Magic Johnson promises to
LAS VEGAS-- Samaritan Pharmaceuticals Inc. and Samaritan Research Labs, Georgetown University, are pleased to announce they have made further product development milestones with their HIV products. Independent testing protocols have provided impressive efficacy data to suggest the SP-01A compound has promise as an HIV
BASKING RIDGE, N.J.-- Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. announces the completion of its 6 month clinical pilot study Evaluating the Effects of RESURGEX(R) on Metabolic, Virological, and Immunological Parameters in HIV/AIDS Patients The goal of the study
LOS ANGELES--Defending champion Annika Sorenstam and fellow Swedes Carin Koch, Maria Hjorth, and Liselotte Neumann will play in the Office Depot Championship Hosted by Amy Alcott, March 29-April 4, at El Caballero Country Club in Tarzana. The Consulate General of Sweden Los Angeles is sponsoring a reception and present
BEVERLY HILLS, Calif. -- Vencor International, Inc., announced that it is initiating the distribution of FDA approved at-home tests for HIV and other diseases and conditions throughout the United States of America. Home Access Health Corporation of Hoffman Estates, Illinois, makes the only U.S. Food and Drug Administra
SALVADOR DA BAHIA, Brazil-- Enzo Biochem, Inc. scientists at a medical conference here presented results of a preclinical study in an animal model system evaluating one of the Company s new immunemodulatory agents, glucosylceramide (GC), as a potential therapeutic for treating immune mediated diseases. GC is a compound
WOBURN, Mass. -- Aphios Corporation has been awarded a Small Business Innovative Research (SBIR) Advanced Technology Phase I grant from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) to develop novel anti-HIV therapeutics from its unique library of marine microorg
NEWPORT BEACH, Calif.--Acacia Research Corporation announced today that its CombiMatrix group is expanding its collaboration with the research group of Professor Bonaventura Clotet, M.D., Ph.D., of the Retrovirology Laboratory irsiCaixa, to conduct the initial efficacy screening of pooled siRNA compounds against the
BETHLEHEM, Pa. -- OraSure Technologies, Inc. announced today that the U.S. Food and Drug Administration ( FDA ) has approved the Company s new OraQuick(R) Rapid HIV-1/2 Antibody Test. This approval will allow the simultaneous detection of antibodies to both the HIV-1 and HIV-2 viruses in finger stick and venipuncture w
NEW YORK -- The company has prepared for this news for the last 3 months and clearly has the first mover advantage. This is what Warren Eugene is terrific at. He recognizes and acts on opportunities. States, Peter Hilton Mijovick Secretary of Amigula Inc. The Canadian government has approved a pilot project in British
SAN DIEGO -- A new survey indicates America s young doctors are still at risk for potentially deadly injuries from suture needles. The survey is described in an article in the Winter 2004 issue of AOHP Journal, the publication of the Association of Occupational Health Professionals in Healthcare (AOHP). Researchers fou
BOUNTIFUL, Utah -- Specialized Health Products International, Inc., a leader in the design and development of medical safety needles, today announced that its fourth quarter and year-end 2003 financial results conference call will be held on Thursday, March 25, 2004 at 4:30 p.m. EST. Consolidated financial results for
STANFORD, Calif. -- Taking advantage of the open-air laboratory that is San Francisco, Peter Small, MD, has collected samples of virtually every case of tuberculosis that has occurred in the city for the last 13 years -- almost 3,000 total. In this week s advance online edition of The Proceedings of the National Academ
FOSTER CITY, Calif. -- Gilead Sciences , Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for marketing approval of a fixed dose co-formulation of the company s anti-HIV medications
WASHINGTON -- Studies examining the benefits and risks of prescribed and over-the-counter drugs and research exploring new drug applications will be presented at the March 24-27 annual meeting of the American Society for Clinical Pharmacology and Therapeutics at the Fountainebleau Hilton Resort in Miami Beach FL. Learn
RESEARCH TRIANGLE PARK, N.C. -- TheraSim, the world s leading provider of interactive disease simulation diagnostic and treatment training aides, announced today that the first computer-based HIV/AIDS clinical disease-simulation training pilot program will be made available to healthcare providers, clinics, medical ins
BETHLEHEM, Pa. -- OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced that the U.S. Food and Drug Administration ( FDA ) has approved the transfer of manufacturing of its OraSure(R) HIV-1 oral specimen collection device from Oregon to the Company s Bethlehem, Pennsylvania facilities. In l
PHILADELPHIA -- $40,000 Award Will Allow Calcutta House to Continue Pilot Study Designed to Enhance Psycho-social Rehabilitative Services for Those Living with HIV/AIDS in Philadelphia Calcutta House announced today that they have been awarded a GlaxoSmithKline International IMPACT Award in recognition of their work pr
SAN DIEGO -- Hollis-Eden Pharmaceuticals, Inc. today announced the presentation of additional data relating to the molecular mechanism of action by which its immune regulating hormone IMMUNITIN(TM) (HE2000) may regulate the immune system back towards homeostasis when used in the treatment of a variety of disease condit
PHILADELPHIA-- Hemispherx Biopharma, Inc. today announced the authorization by the U.S. Food and Drug Administration ( FDA ) to conduct a clinical trial with Alferon LDO(R) in HIV-infected patients. The submission to the Investigational New Drug Application (IND) for Human Leukocyte Interferon (Alferon N), Oral, ref.
NEW YORK -- WADO 1280 AM listeners in New York showed tremendous support for the kids at St. Jude Children s Research Hospital during the station s third annual Promesa y Esperanza radiothon held on-air February 12-13, 2004. The event established a fund-raising record for the station raising $832,066.00 - nearly $242,0
CARLSBAD, Calif.--The Immune Response Corp. , a biopharmaceutical company dedicated to treating and preventing HIV and AIDS through the development of immune-based therapies, will present at the Institutional Investors Forum 2004 at the Warwick Hotel, New York. Chief Executive Officer John N. Bonfiglio, Ph.D., will mak
MORRISTOWN, N.J. -- Medsn last night received an Award for Excellence for Animation at the Rx Club Show in New York City. The winning Medsn project, Protease Inhibitors: Targeting the HAART of HIV, featured 3D animation to demonstrate the complexity of a new HIV compound, its mechanism of action, and its unique clinica
WATERTOWN, Mass. -- Pathfinder International today announced it has received a $9,483 grant from the Elton John AIDS Foundation to support an HIV/AIDS education program aimed at the religious leaders of candomble temples in Salvador, Brazil . The project will be implemented in the impoverished cities of Salvador and Fe
SAN FRANCISCO -- Incyte Corporation and Pharmasset, Inc., its strategic collaborative and licensing partner for Reverset(TM), announced today the results of a 10-day Phase II dose-escalating, placebo-controlled trial designed to evaluate the anti-viral effects and safety of Reverset as monotherapy in 30 treatment-naive
PRINCETON, N.J.-- Technology Licensed to Locus Pharmaceutical; Sarnoff Continuing to Pursue New Approaches Sarnoff Corporation, the Princeton-based innovation services and technology development company, praised the announcement from Locus Pharmaceuticals of Blue Bell, PA, that the U.S. Patent and Trademark Office has
BLUE BELL, Pa.-- Technology is Being Successfully Applied in Advancing Development Programs to Treat HIV, Cancer and Arthritis Locus Pharmaceuticals today announced that it has received a Notice of Allowance from the US Patent and Trademark Office for an innovative computational method for the design of new drugs. This
ALAMEDA, Calif.-- Upgraded Software Now Available in the United States ; CE Mark Certification Completed for Europe Celera Diagnostics, a joint venture between the Applied Biosystems Group and Celera Genomics Group of Applera Corporation, today announced that it has obtained special 510(k) clearance from the U.S. Food
SAN CARLOS, Calif. -- Substantial Pain Decreases From a Single 1-Hour Topical Treatment Sustained for 12 Weeks NeurogesX, Inc. announced today results from an open-label, multi-center study evaluating NGX-4010, a novel high-concentration trans-capsaicin dermal delivery system in patients with painful HIV-associated neu
WILMINGTON, Del. & ATLANTA -- Incyte Corporation and Pharmasset Inc. announced that preliminary results of a 10-day Phase II dose-escalating, placebo-controlled trial designed to evaluate the anti-viral effects and safety of Reverset(TM) demonstrated a significant reduction in viral load in treatment-naive patients
BETHLEHEM, Pa. -- OraSure Partners with HIV Testing Sites Across the Country to Encourage Rapid HIV Testing with OraQuick(R) OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test will be utilized by numerous locations across the
FOSTER CITY, Calif.-- Gilead Sciences , Inc. today announced preliminary three-year (144-week) data from a double-blind Phase III clinical trial (Study 903) suggesting that Viread (R) ( tenofovir disoproxil fumarate) is ass
FOSTER CITY, Calif.-- Gilead Sciences , Inc. today announced that the company, for strategic reasons, is ending its licensing agreement with Emory University and the University of Georgia Research Foundation, Inc. for the development and commercialization of amdoxovir. Also known as DAPD, amdoxovir is an investigationa
BASKING RIDGE, N.J. -- Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. announces that in addition to obtaining New York Medicaid approval, Resurgex(R), is now being reimbursed under the New York AIDS Drug Assistance Program (ADAP) which provides free medications and
LA JOLLA, Calif. -- Aethlon Medical, Inc. announced that it will be a featured presenter at the 6th International Conference on Dialysis which starts tomorrow in Rio Grande, Puerto Rico . Aethlon s Chief Scientific Officer, Dr. Richard Tullis, will discuss the biological mechanisms that cause the transition from HIV in
BETHLEHEM, Pa. -- OraSure Technologies, Inc., the market leader in oral fluid diagnostics, announced today that its OraQuick(R) Rapid HIV-1 Antibody Test has received the prestigious 2003 Photonics Circle of Excellence Award. This Award is bestowed annually on the 25 most technically innovative new products of the year
SAN FRANCISCO -- The Institute for OneWorld Health, a nonprofit pharmaceutical company, announced that it is only a year away from seeking approval for its first medicine, a drug to cure a deadly parasitic disease in India . The announcement came from Founder and CEO Victoria Hale, Ph.D. Dr. Hale was invited to speak a
BOSTON -- Last week, the William Jefferson Clinton Presidential Foundation announced an unprecedented agreement with five of the world s leading medical technology companies to significantly reduce the price of HIV/AIDS tests for countries with the largest HIV/AIDS populations. Richard J. Zall, a partner in Mintz Levin
SEATTLE-- Xcyte Therapies, Inc. today announced that it will collaborate with Fresenius Biotech GmbH, a division of Fresenius AG, in a T cell-based gene therapy program for treating HIV infection. The program is focused on restoring HIV-infected patients immune systems by administering gene-modified T cells that are re
LAS VEGAS-- Samaritan Pharmaceuticals Inc. -- Inhibitory Effects of Procaine Reported in The Journal of Pharmacology and Experimental Therapeutics -- Expanded Understanding Lends Credence to the Increasing Speculation that Cholesterol-Depleting Drugs Might Suppress HIV Replication Samaritan Pharmaceuticals Inc. and Sam
NEW YORK-- Enzo Biochem, Inc., a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, said today that the Phase I/II study of its Stealth Vector(R) HGTV43(TM) gene construct for HIV infection has been initiated at N
TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. announced today that it has initiated a second pivotal phase 3 clinical trial of its investigational drug methylnaltrexone (MNTX) for the treatment of opioid-induced constipation in patients with advanced medical illness (AMI). Constipation is a serious medical problem
PHILADELPHIA -- Hemispherx Biopharma, Inc. announced today that it will convene a national panel of clinical experts on January 16, 2004 to review its upcoming clinical program.The attendees include researchers from the Pasteur Institute of France , the University of Virginia, Cornell University and others, as well as
This information is designed to support, not replace, the relationship that exists between you and your doctor.